ONTRACK BIOMEDICAL AG

ONtrack Biomedical AG strives towards improving the quality of life of patients by developing in-vitro diagnostic tests for early and non-invasive detection and monitoring of cancer. ONtrack Biomedical’s first pipeline product, PROBAN, is a urine test to improve prostate cancer diagnosis and, thus, the eligibility criteria for prostate biopsy. PROBAN aims at reducing the pressure on patients and health systems with better informed decisions for the downstream healthcare choices and decreasing the associated cost burden.